A new interactive map of the surface of SARS-CoV-2, featuring the Spike, Envelope and Membrane proteins, has been released for researchers to use.
List view / Grid view
Filter the results
A pocket in the SARS-CoV-2 Spike protein has been discovered by researchers, who say it could be a drug target for COVID-19.
The non-infectious quantum dot probes are designed to enable researchers to safely study interactions between the SARS-CoV-2 Spike (S) protein and human cells.
According to researchers, the DMBT1S8 molecule can halt inflammation in the respiratory tract through its interaction with the Siglec-8 receptor on immune cells.
Researchers showed CXCL1 signalling to neutrophils drove brain inflammation in herpes simplex virus (HSV) encephalitis and blocking the protein resulted in less severe disease.
Researchers studying the PLpro binding site of three coronaviruses, including SARS-CoV-2, say the BL2 loop could be targeted by antiviral drugs.
By editing out a set of proteins on the surface of human pluripotent stem cells, researchers have ensured they will be not be rejected by the body's immune system.
Scientists have found two active substances that allowed cells to reactivate the production of a protein that prevents the onset of Parkinson's disease.
Exploring the intra-protein non-covalent interactions in the S1 domain of the SARS-CoV-2 S1 Spike protein
The Spike (S) protein is a promising drug target in the quest to develop vaccines and antivirals for SARS-CoV-2 to treat and prevent COVID-19. Intra-protein interaction energy landscape mapping efforts have recently identified key interactions that may be crucial for the S protein’s ability to bind to receptor proteins on…
The National Institute of Health envisions a plan for managing tuberculosis in the 21st century. Included in this proposal is targeting host proteins as an add-on therapy to antibiotics. Infectious disease biologists are focusing on this strategy and it is a topic of active research. Recently, a multinational research team…
IN NOVEMBER 2017, leadXpro chose to strengthen its capabilities with the Creoptix™ WAVEsystem. “We were looking for a label‑free, biophysical method to investigate binding affinity and kinetics of small molecules with challenging integral membrane proteins,” explained Michael Hennig, Chief Executive Officer of leadXpro.
Researchers have revealed that the antibiotic concanamycin A targets a protein called Nef, allowing the immune system to destroy HIV in cells.
Taylor B Guo, Chief Scientific Officer at I-Mab, describes the potential benefits of bispecific antibodies for cancer therapy and how their dual targeting mechanisms of action may drive their emergence as the next generation of immuno-oncology drugs.
In 2019, the SARS-CoV-2 coronavirus sparked a global pandemic that is likely to continue into 2021. Effective therapeutics that treat the symptoms of the disease and prevent or treat the underlying viral infection are critically required. To meet this need, the global biopharmaceutical industry is evaluating over 50 monoclonal antibody…